

Analytical Methods

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43



Diseased



Healthy



1
2
3 **Determination of Methylarginines in Infant Plasma by CE-LIF**
4
5
6

7
8 Thomas H. Linz^{1,3**} and Susan M. Lunte^{1,2,3*}
9

10
11
12 Departments of Chemistry¹ and Pharmaceutical Chemistry² and the Ralph N. Adams Institute for
13
14 Bioanalytical Chemistry³; University of Kansas, Lawrence, KS
15
16
17

18
19
20 *Corresponding author
21

22 Dr. Susan Lunte
23

24 Ralph N. Adams Institute for Bioanalytical Chemistry
25

26
27 University of Kansas
28

29 2030 Becker Dr. MRB 220
30

31 Lawrence, KS 66047
32

33
34 slunte@ku.edu
35

36 Fax: 785-864-1916
37
38
39

40
41 ** Current address:
42

43 Dr. Thomas Linz
44

45 Department of Chemistry,
46

47 University of North Carolina,
48

49 Chapel Hill, NC
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Analytical Methods Accepted Manuscript

Abstract

Methylarginines (MAs) are a class of nitric oxide synthase inhibitors that have been implicated in respiratory complications of critically ill infants. This paper describes the development of an analytical method to measure these compounds in the plasma of newborns using capillary electrophoresis (CE). The CE separation method was optimized to enable complete baseline resolution of the four MA analogues of interest. Sample preparation concerns for infant-derived samples were addressed by validating a heat-assisted extraction method for the analysis of low volume (≤ 100 μL) samples from a plasma matrix. It was determined that the sample matrix (plasma versus serum) did not affect the measured MA concentrations, while extracting smaller volumes of plasma that underwent heat-induced gelation afforded higher MA recoveries than larger volume samples. These methods were then applied to blood samples collected from infants housed in the neonatal intensive care unit. It was discovered that these newborns had significantly elevated concentrations of MAs at younger ages (< 6 months) while amounts were similar between infants 6 months old and adults. The data are preliminary, but demonstrate an interesting age dependence on the concentrations of these nitric oxide inhibitors, which has not been previously reported.

Introduction

A common characteristic of most clinical diagnostic tests is that they rely on technology that can be implemented on a large scale and in a cost-effective manner.¹ Assays that produce colorimetric changes are ideal since they can be readily discerned either by using absorbance detection with conventional multiwell-plate technology or visually with simple point-of-care devices.² Each facilitates rapid analysis to achieve high sample throughput. However, in order to be effective, these assays must be highly selective for a given analyte and demonstrate very low cross-reactivity. This typically necessitates that only a single analyte be measured per assay; therefore, multiple assays must be employed to measure a range of biomarkers. Although this is not problematic in most routine analyses, in situations where an immediate response is necessary, waiting hours to days for a hospital lab to measure all the markers of interest can jeopardize the health of that patient. This problem is further exacerbated in the analysis of samples derived from infants, especially those in the neonatal intensive care unit (NICU). Given the poor health of infants in the NICU and considering that many of them were born prematurely, limitations exist in the volume of blood that can be collected. This sample volume restriction may prevent all of the desired assays from being conducted, and may also restrict the assays to the analysis of plasma instead of less complex serum.³ Considering the severe time constraints placed on diagnosing newborns in the NICU, it would be highly beneficial for a method to rapidly measure multiple analytes within a single assay from a small volume of plasma.

Capillary electrophoresis (CE) is an analytical technique that can be used to separate multiple analytes in a single assay from a sub-microliter volume sample. However, prior to the analysis of a biological sample, sample preparation steps must frequently be undertaken to allow the sample

1
2
3 to be compatible with the analysis technique.⁴ Most often this is accomplished by protein
4 precipitation followed by solid-phase extraction (SPE) or affinity-based separation methods.⁵
5
6 However, such procedures are generally complicated and labor-intensive. A recently reported
7
8 heat-assisted extraction method was developed by our group to alleviate these concerns by
9
10 expediting the sample preparation to enable higher sample throughput than SPE with far lower
11
12 cost.⁶
13
14
15
16

17
18 This paper describes the development of a CE-based method to measure methylarginines
19
20 (MAs) in infant plasma. MAs (Figure 1) are a class of compounds that inhibit the synthesis of
21
22 nitric oxide (NO) *in vivo*. The concentrations of monomethylarginine (MMA), asymmetric
23
24 dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) (and their endogenous ratios)
25
26 have been shown to serve as biomarkers for a multitude of NO-related pathologies, including
27
28 cardiovascular diseases and pulmonary hypoxia.⁷⁻¹⁰ In this study, blood samples obtained from
29
30 critically ill newborns were analyzed to determine the correlation between NO deficiency and
31
32 their severe medical condition. Given the central role that NO plays in the pulmonary system and
33
34 the fact that respiratory distress is prevalent in newborns in the NICU, we hypothesized that
35
36 these infants would exhibit diminished NO production due to elevated MA concentrations. The
37
38 desire to analyze infant-derived samples necessitated that the analytical method be optimized and
39
40 validated for the analysis of low-volume samples ($\leq 100 \mu\text{L}$) from a plasma matrix, which has not
41
42
43
44
45
46 been previously described.
47
48
49
50

51 **Materials and methods**

52 **Reagents**

53
54
55
56
57
58
59
60

Standards of MMA, ADMA, SDMA, and propylarginine (PA) were purchased from Enzo Life Sciences (Farmingdale, NY). Sodium tetraborate and sodium cyanide were obtained from Sigma Aldrich (St. Louis, MO). Naphthalene-2,3-dicarboxaldehyde (NDA) and sulfobutylether- β -cyclodextrin (SBEC) were acquired from Invitrogen (Carlsbad, CA) and Cydex Pharmaceuticals (Lenexa, KS), respectively. HPLC-grade dimethylsulfoxide, acetonitrile, and formic acid were purchased from Fisher Scientific (Pittsburgh, PA). All solutions were prepared with 18.2 M Ω ·cm deionized water (Millipore, Billerica, MA). Serum samples from anonymous adults were acquired at Lawrence Memorial Hospital (Lawrence, KS). Scavenged plasma samples were collected from infants in the NICU at Children's Mercy Hospital (CMH) (Kansas City, MO). The procedure was approved by the CMH Institutional Review Board (IRB) and collected under the direction of Michael Norberg and Dr. William Truog at CMH. All samples were stored at -80 °C until ready for analysis at KU.

Heat-assisted extraction procedure

To prepare the adult serum samples, aliquots of pooled serum (25–100 μ L) were transferred into 2 mL polypropylene microcentrifuge tubes (Fisher Scientific) to which 5% (v/v) of 10 μ M PA (1.25–5 μ L) was added. For the infant samples, 25 μ L of plasma was mixed with 1.25 μ L of 10 μ M PA. All tubes were immersed in boiling water (100 °C) for 1.5 min. During the heating process, the liquid serum quickly congealed to form a solid gel. Once the serum gel was formed, water was added to each vial at a volume identical to the initial serum volume (*e.g.*, 25 μ L water into 25 μ L serum gel) and the vials were vortexed for \sim 20 s for a near no-net-dilution extraction. Samples were allowed to incubate for 5 min at room temperature and were then centrifuged to

1
2
3 sediment the aggregated proteins.⁶ The supernatants were decanted into separate tubes for
4
5 subsequent CE analysis.
6
7
8
9

10 **Capillary electrophoresis**

11
12 A Beckman P/ACE MDQ CE instrument (Brea, CA) with a 50 μm i.d. capillary (Polymicro
13
14 Technologies; Phoenix, AZ) 65 cm in length (50 cm to window) was utilized in this study. The
15
16 run buffer consisted of 15 mM sodium tetraborate, 10 mM SBEC, and 28% (v/v) DMSO.
17
18 Samples were injected hydrodynamically at 1.0 psi for 5.0 s, and separations were carried out at
19
20 an applied field strength of 460 V/cm. A 445 nm diode laser (CrystaLaser; Reno, NV) was used
21
22 to stimulate fluorescence emission which was measured with an external laser-induced
23
24 fluorescence (LIF) detector (Picometrics; Ramonville, France). 32 Karat software (Beckman)
25
26 fluorescence (LIF) detector (Picometrics; Ramonville, France). 32 Karat software (Beckman)
27
28 was used to operate both CE operation and LIF detection.
29
30
31

32 Samples analyzed by CE were first derivatized with NDA/CN. NDA was dissolved in 1 : 1
33
34 acetonitrile : water; all other solutions were prepared in deionized water. The derivatization
35
36 procedure entailed combining equal volumes of sample, 50 mM sodium tetraborate, NDA, and
37
38 5 mM NaCN and allowing the mixture to react for 10 min prior to injection. The initial NDA
39
40 concentration was 1 mM when derivatizing standards and 5 mM when derivatizing blood
41
42 samples. Peak areas from both standards and serum samples were normalized to the area of the
43
44 non-endogenous internal standard, PA, for quantitation. All standards were measured in
45
46 triplicate. Serum samples from adults were analyzed by CE-LIF once each, while infant samples
47
48 were analyzed in duplicate.
49
50
51
52
53
54

55 **Results and discussion**

56
57
58
59
60

CE separation optimization

A CE-LIF method for the determination of the four MAs involved in NO synthase regulation using NDA/CN derivatization was previously reported by our group.^{6, 11} Baseline resolution between the analytes of interest was obtained with a run buffer containing borate, SBEC, and DMSO. This method was capable of quantifying endogenous MA concentrations in adult serum; however, the reproducibility of the separation was somewhat variable. Specifically, for a few of the analyses, the resolution between the peaks for MMA and an unknown endogenous analyte was diminished to the point where quantitation of MMA was precluded. To prevent this issue from affecting the study described here, the CE method was further optimized using pooled serum from unidentified adult donors.

In an attempt to improve separation resolution, several run buffer modifiers were investigated, including modified cyclodextrins, surfactants, and organic solvents. Following these studies, it was ultimately determined that the best and most reproducible results were obtained by simply adjusting the DMSO content. Baseline resolution between MMA and the unknown compound was achieved by increasing the amount of DMSO in the run buffer from the previous optimum of 25% to 28%. While the resolution between MMA and PA was slightly reduced under this set of conditions, it permitted more precise peak integration. Under these conditions, the unknown peak in serum samples split into two distinct peaks. Increasing the percentage of DMSO in the run buffer caused one of them to migrate earlier in the electropherogram, while the other migrated after PA (Figure 2). Therefore, the MA peaks of interest were no longer obscured by the interfering compounds, allowing more precise quantitation. The migration times also increased as a result of the additional DMSO; therefore, the separation voltage was increased to 460 V/cm, which generated a similar total analysis time

1
2
3 without diminishing resolution. This optimal separation was utilized for all future analyses. Peak
4 identities in clinical samples were verified by spiking experiments (Figure S11).
5
6
7
8
9

10 **Effect of sample volume on recovery**

11
12 In an effort to make the heat-assisted extraction method more amenable to the analysis of
13 samples from infants, a reduction in the required sample volume was sought. First, validation of
14 the extraction recovery was required to ensure that the utilization of smaller volumes of serum
15 would not be detrimental to the analysis. Therefore, aliquots of 100 μL , 50 μL , and 25 μL from a
16 pooled lot of adult serum were dispensed into separate vials into which 5 μL , 2.5 μL , and 1.25
17 μL of 10 μM PA was added (each sample was prepared in triplicate), respectively, to hold the
18 ratio of serum-to-water constant for each sample. Samples were heated until a serum gel formed
19 and were then extracted into a volume of water identical to the original volume of serum for a
20 near no-net-dilution extraction prior to analysis.
21
22
23
24
25
26
27
28
29
30
31
32
33

34
35 It was determined from this experiment that the volume of extracted serum impacted the
36 recoveries of the MAs. Figure 3 illustrates that the recovered fraction for each MA analogue was
37 higher on average for the smaller volume samples. This improvement can be attributed to a
38 larger solvent-accessible surface area of the serum gel. Thinner serum-clots better allowed the
39 extraction solvent to penetrate into the gel and resolubilize the analytes trapped within the
40 aggregated protein framework. Smaller initial serum volumes (25 μL) enabled recoveries of
41 ~90% as opposed to the ~60% recovery observed with larger serum volumes (100 μL). This
42 finding demonstrates not only the analytical benefit of conducting experiments with smaller
43 sample volumes (*i.e.*, more efficient extractions) but also the clinical benefit of requiring less
44 blood to be drawn from infants. The high variance observed for the recoveries can be primarily
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 attributed to inconsistency in the serum gel. The post-extraction sample volume differed due to
4 variability in gel water retention by as much as $\pm 20\%$ from the volume incubated with the gel.
5
6 These volume discrepancies exhibited an appreciable effect on the extracted analyte
7 concentration. This effect was further accentuated after normalization of the data to the standard
8 curve for recovery determination where the errors of the analyses were compounded. However,
9 given that the recovered volume impacted all analytes of interest to similar extents, the
10 differences in average recoveries were found to be significant.
11
12
13
14
15
16
17
18
19
20
21

22 **Effect of sample matrix**

23
24 The method described in our previous report utilized serum for MA analysis.⁶ However, when
25 conducting studies involving infants in the NICU, insufficient blood volumes are collected to
26 allow whole blood to be effectively converted into serum using standard clot-activating vials.
27 Therefore, the studies here were limited to the use of plasma. While serum and plasma matrices
28 are similar in their pH, ionic strengths, and high protein content, serum is a less complex matrix
29 compared to plasma, which contains additional clotting proteins. Additionally, it has been shown
30 that the concentrations of various analytes may not be identical between the two matrices.^{12, 13}
31 Therefore, an investigation was performed into whether the specific blood matrix (*i.e.*, plasma or
32 serum) impacted MA recovery following the heat-prep method.
33
34
35
36
37
38
39
40
41
42
43
44
45

46 To determine if a difference would be observed between serum and plasma in MA
47 quantitation, whole blood was drawn from a single adult and split into two fractions—one
48 aliquot was converted to plasma and the other to serum. Each sample underwent heat-assisted
49 extraction followed by CE-LIF analysis under the optimized separation conditions. Table 1
50 compares the concentrations of MAs present in serum versus plasma. The results indicated that
51
52
53
54
55
56
57
58
59
60

1
2
3 no significant difference existed between the two matrices (based on a two-tailed t-test; $p > 0.45$
4 for each analyte). This finding was anticipated since the additional proteins from the plasma
5 should have denatured and incorporated into the gel framework without impacting the extraction
6 of small molecules from the gel. The similarity between the matrices will allow plasma samples
7 from newborns to be analyzed without fear of matrix-related bias.
8
9

17 **Determination of MAs in clinical samples**

19
20 Upon validating that the analytical method permitted the analysis of low volume plasma samples,
21 an investigation was performed to determine the concentrations of MAs in the plasma of
22 critically ill infants housed in the NICU. The results showed that these newborns had very high
23 amounts of MAs (Figure 4a), particularly during the first month of life. These high
24 concentrations were consistent with the few existing reports in the literature concerning MA
25 concentrations in newborn plasma.¹⁴⁻¹⁶ Significant differences were observed ($p < 0.05$ for each
26 analyte) between patients of different ages, especially with SDMA, which first increased in
27 concentration and then diminished. ADMA and MMA maintained similar concentrations initially
28 but then exhibited a significant concentration reduction as the infants aged. Further correlation
29 with disease state could not be performed due to the fact that samples were supplied to us from
30 unidentified newborns with only their ages made available. Future experiments will explore the
31 link between the elevations of MA concentrations and the etiology of the disease to elucidate the
32 biochemical pathways involved.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 For comparison purposes, blood samples were also analyzed from anonymous adult donors
51 ($n = 17$). The average ADMA and SDMA concentrations from these adult samples were
52 $< 0.5 \mu\text{M}$; these were substantially lower than the values obtained from infants, which exceeded
53
54
55
56
57
58
59
60

1
2
3 1 μM in the first 1+ month of life (Figure 4b). The MA concentrations decreased significantly as
4
5 a function of age. Once infants reached 6 months of age, their MA concentrations were similar to
6
7 those observed in adults.
8
9

10
11 The higher MA concentrations found in infants are in line with values that have been
12
13 previously reported.¹⁴⁻¹⁶ However, this is the first report demonstrating the age-dependence of
14
15 the amount of endogenous MAs. These findings offer interesting insight into the NO pathway of
16
17 infants. Given the inter-dependence of many compounds on the amount of NO produced, the
18
19 increased MA concentrations and potential NO inhibition beget the question of whether other
20
21 NO pathway-related molecules are also at atypical levels in critically ill infants. Disregulation of
22
23 dimethylarginine dimethylaminohydrolase (DDAH) or protein arginine methyltransferase
24
25 (PRMT) could lead to higher MA concentrations.¹⁷ It has been reported that DDAH expression
26
27 and activity increases before birth and then declines thereafter, which may help explain the
28
29 observed trend.¹⁰ A more thorough investigation of this pathway could provide better
30
31 information regarding the role that MAs play in neonatal diseases related to NO. This could
32
33 potentially lead to the design of medications to target the underlying problems affecting these
34
35 infants.
36
37
38
39

40
41 Other alternative potential reasons for the observation of elevated MA concentrations in
42
43 newborn plasma could stem from an artifact of sample collection. All newborn-derived samples
44
45 had some evidence of hemolysis. Reports have shown that red blood cells (RBCs) contain a
46
47 clinically relevant amount of MAs.^{18, 19} If the RBCs in the samples lysed during collection, they
48
49 could have artificially increased the observed MA concentrations and biased the results;
50
51 however, not to the extent observed in Figure 4a.
52
53
54
55
56
57
58
59
60

Conclusions

This report demonstrates the application of a new sample preparation and separation method to the analysis of clinical samples. CE-LIF separation and heat-assisted extraction methods were developed to analyze low volume plasma samples, which were then applied to a small-scale study analyzing samples collected from newborns in the NICU. The results from this preliminary study indicated that these infants had extremely high MA concentrations compared to adults. The elevated concentrations in the newborns indicate that they may suffer from NO-related pathologies, which may be the reason for their hospitalization. However, at six months of age, it was shown that the MA concentrations diminished to those found in adults. This is the first study to chart the amounts of MAs over the first several months of life. Future work will delve into the involvement of MAs in disease onset. The analytical method will also be modified to conduct the CE separation in a microfluidic platform to enable more rapid point-of-care diagnostics in a clinical setting.

Acknowledgements

The authors would like to thank Dr. Roger Dreiling, Connie Broers, and Faith Nilhas at Lawrence Memorial Hospital and Dr. William Truog and Michael Norberg at Children's Mercy Hospital for obtaining IRB permission and collecting the blood samples for this study. The authors would also like to acknowledge the American Heart Association for a predoctoral fellowship, NIH R21NS061202, and the Adams Institute for funding. We would also like to thank Nancy Harmony for her editorial assistance with the manuscript.

5. References

1. F. J. Bamforth, *Clin. Biochem.*, 1994, **27**, 333-342.
2. C. V. Sapan, R. L. Lundblad and N. C. Price, *Biotechnol. Appl. Biochem.*, 1999, **29**, 99-108.
3. S. J. Hyman, Y. Novoa and I. Holzman, *Pediatr. Clin. N. Am.*, 2011, **58**, 1083-1098.
4. M. L. Chiu, W. Lawi, S. T. Snyder, P. K. Wong, J. C. Liao and V. Gau, *JALA*, 2010, **15**, 233-242.
5. S. Tulipani, R. Llorach, M. Urpi-Sarda and C. Andres-Lacueva, *Anal. Chem.*, 2013, **85**, 341-348.
6. T. H. Linz and S. M. Lunte, *Electrophoresis*, 2013, **34**, 1693-1700.
7. Z. Wang, W. H. W. Tang, L. Cho, D. M. Brennan and S. L. Hazen, *Arterioscler., Thromb., Vasc. Biol.*, 2009, **29**, 1383-1391.
8. D. Zakrzewicz and O. Eickelberg, *BMC Pulm. Med.*, 2009, **9**, 5.
9. R. A. Dweik, *Am. J. Physiol. Lung Cell Mol. Physiol.*, 2007, **292**, L15-17.
10. F. I. Arrigoni, P. Vallance, S. G. Haworth and J. M. Leiper, *Circulation*, 2003, **107**, 1195-1201.
11. T. H. Linz, C. M. Snyder and S. M. Lunte, *J. Lab. Autom.*, 2012, **17**, 24-31.
12. D. C. Wedge, J. W. Allwood, W. Dunn, A. A. Vaughan, K. Simpson, M. Brown, L. Priest, F. H. Blackhall, A. D. Whetton, C. Dive and R. Goodacre, *Anal. Chem.*, 2011, **83**, 6689-6697.
13. O. Teahan, S. Gamble, E. Holmes, J. Waxman, J. K. Nicholson, C. Bevan and H. C. Keun, *Anal. Chem.*, 2006, **78**, 4307-4318.
14. G. I. M. Di, L. Chiandetti, A. Gucciardi, V. Moret, M. Naturale and G. Giordano, *Anal. Chim. Acta*, 2010, **677**, 140-148.
15. G. Vida, E. Sulyok, T. Ertl, J. Martens-Lobenhoffer and S. M. Bode-Boeger, *Pediatr. Int.*, 2012, **54**, 476-479.
16. M. A. Bordigato, D. Piva, G. I. M. Di, G. Giordano, L. Chiandetti and M. Filippone, *Early Hum. Dev.*, 2011, **87**, 143-145.
17. P. Bulau, D. Zakrzewicz, K. Kitowska, J. Leiper, A. Gunther, F. Grimminger and O. Eickelberg, *Am. J. Physiol. Lung Cell Mol. Physiol.*, 2007, **292**, L18-24.
18. M. Davids, A. J. van Hell, M. Visser, R. J. Nijveldt, P. A. M. van Leeuwen and T. Teerlink, *Am. J. Physiol. Heart Circ. Physiol.*, 2012, **302**, H1762-1770.
19. S. S. Billecke, L. A. Kitzmiller, J. J. Northrup, S. E. Whitesall, M. Kimoto, A. V. Hinz and L. G. D'Alecy, *Am. J. Physiol.*, 2006, **291**, H1788-H1796.

Figure Captions

Figure 1. Structures of the methylarginines involved in nitric oxide synthase inhibition pathways. Arg: arginine; MMA: monomethylarginine; ADMA: asymmetric dimethylarginine; SDMA: symmetric dimethylarginine.

Figure 2. CE separation (430 V/cm) of standards (black) and adult serum samples (red) with 25% and 28% DMSO in the run buffer. Two unknown peaks resolve from the MMA peak when DMSO is increased to 28%. All MA peak identities in blood samples were verified based on spiking the serum with the authentic compound.


Figure 3. Effects of initial serum volume on extraction recoveries of MAs from serum gel.

Figure 4. (a) Concentrations of MAs in the plasma of newborns of various ages. (b) Comparison of the concentrations of MAs between newborns and adults.

* $p < 0.05$; ** $p < 0.001$


Table 1. Comparison of the effect of blood sample matrix on MA quantitation.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Analytical Methods Accepted Manuscript

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Analytical Methods Accepted Manuscript

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

b)



Analytical Methods Accepted Manuscript